BR0009885A - Derivados de ácido carbâmico e sua aplicação como ligantes de receptor de glutamato metabotrópico - Google Patents

Derivados de ácido carbâmico e sua aplicação como ligantes de receptor de glutamato metabotrópico

Info

Publication number
BR0009885A
BR0009885A BR0009885-0A BR0009885A BR0009885A BR 0009885 A BR0009885 A BR 0009885A BR 0009885 A BR0009885 A BR 0009885A BR 0009885 A BR0009885 A BR 0009885A
Authority
BR
Brazil
Prior art keywords
glutamate receptor
metabotropic glutamate
application
acid derivatives
carbamic acid
Prior art date
Application number
BR0009885-0A
Other languages
English (en)
Inventor
Konrad Bleicher
Vicent Mutel
Eric Vieira
Juergen Wichmann
Thomas Johannes Woltering
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Publication of BR0009885A publication Critical patent/BR0009885A/pt

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D213/00Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/24Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D213/28Radicals substituted by singly-bound oxygen or sulphur atoms
    • C07D213/30Oxygen atoms
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/06Antimigraine agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/14Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/14Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16Anti-Parkinson drugs
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/18Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/22Anxiolytics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/24Antidepressants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/30Drugs for disorders of the nervous system for treating abuse or dependence
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/30Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/34Tobacco-abuse
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00Drugs for disorders of the senses
    • A61P27/02Ophthalmic agents
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C233/00Carboxylic acid amides
    • C07C233/90Carboxylic acid amides having nitrogen atoms of carboxamide groups further acylated
    • C07C233/91Carboxylic acid amides having nitrogen atoms of carboxamide groups further acylated with carbon atoms of the carboxamide groups bound to acyclic carbon atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C271/00Derivatives of carbamic acids, i.e. compounds containing any of the groups, the nitrogen atom not being part of nitro or nitroso groups
    • C07C271/62Compounds containing any of the groups, X being a hetero atom, Y being any atom, e.g. N-acylcarbamates
    • C07C271/64Y being a hydrogen or a carbon atom, e.g. benzoylcarbamates
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C333/00Derivatives of thiocarbamic acids, i.e. compounds containing any of the groups, the nitrogen atom not being part of nitro or nitroso groups
    • C07C333/02Monothiocarbamic acids; Derivatives thereof
    • C07C333/10Monothiocarbamic acids; Derivatives thereof having nitrogen atoms of thiocarbamic groups being part of any of the groups, X being a hetero atom, Y being any atom, e.g., N-acyl-thiocarbamates
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D213/00Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/61Halogen atoms or nitro radicals
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D263/00Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings
    • C07D263/02Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings
    • C07D263/30Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D263/34Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D263/48Nitrogen atoms not forming part of a nitro radical
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D271/00Heterocyclic compounds containing five-membered rings having two nitrogen atoms and one oxygen atom as the only ring hetero atoms
    • C07D271/02Heterocyclic compounds containing five-membered rings having two nitrogen atoms and one oxygen atom as the only ring hetero atoms not condensed with other rings
    • C07D271/061,2,4-Oxadiazoles; Hydrogenated 1,2,4-oxadiazoles
    • C07D271/071,2,4-Oxadiazoles; Hydrogenated 1,2,4-oxadiazoles with oxygen, sulfur or nitrogen atoms, directly attached to ring carbon atoms, the nitrogen atoms not forming part of a nitro radical
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D271/00Heterocyclic compounds containing five-membered rings having two nitrogen atoms and one oxygen atom as the only ring hetero atoms
    • C07D271/02Heterocyclic compounds containing five-membered rings having two nitrogen atoms and one oxygen atom as the only ring hetero atoms not condensed with other rings
    • C07D271/101,3,4-Oxadiazoles; Hydrogenated 1,3,4-oxadiazoles
    • C07D271/1131,3,4-Oxadiazoles; Hydrogenated 1,3,4-oxadiazoles with oxygen, sulfur or nitrogen atoms, directly attached to ring carbon atoms, the nitrogen atoms not forming part of a nitro radical
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D295/00Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/04Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
    • C07D295/08Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly bound oxygen or sulfur atoms
    • C07D295/084Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly bound oxygen or sulfur atoms with the ring nitrogen atoms and the oxygen or sulfur atoms attached to the same carbon chain, which is not interrupted by carbocyclic rings
    • C07D295/088Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly bound oxygen or sulfur atoms with the ring nitrogen atoms and the oxygen or sulfur atoms attached to the same carbon chain, which is not interrupted by carbocyclic rings to an acyclic saturated chain
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D311/00Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings
    • C07D311/02Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D311/78Ring systems having three or more relevant rings
    • C07D311/80Dibenzopyrans; Hydrogenated dibenzopyrans
    • C07D311/82Xanthenes
    • C07D311/84Xanthenes with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached in position 9
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D333/00Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
    • C07D333/02Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings
    • C07D333/04Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom
    • C07D333/06Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to the ring carbon atoms
    • C07D333/14Radicals substituted by singly bound hetero atoms other than halogen
    • C07D333/16Radicals substituted by singly bound hetero atoms other than halogen by oxygen atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D335/00Heterocyclic compounds containing six-membered rings having one sulfur atom as the only ring hetero atom
    • C07D335/04Heterocyclic compounds containing six-membered rings having one sulfur atom as the only ring hetero atom condensed with carbocyclic rings or ring systems
    • C07D335/10Dibenzothiopyrans; Hydrogenated dibenzothiopyrans
    • C07D335/12Thioxanthenes
    • C07D335/14Thioxanthenes with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached in position 9
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D413/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2601/00Systems containing only non-condensed rings
    • C07C2601/02Systems containing only non-condensed rings with a three-membered ring
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2601/00Systems containing only non-condensed rings
    • C07C2601/06Systems containing only non-condensed rings with a five-membered ring
    • C07C2601/08Systems containing only non-condensed rings with a five-membered ring the ring being saturated
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2601/00Systems containing only non-condensed rings
    • C07C2601/12Systems containing only non-condensed rings with a six-membered ring
    • C07C2601/14The ring being saturated

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Veterinary Medicine (AREA)
  • Psychiatry (AREA)
  • Addiction (AREA)
  • Psychology (AREA)
  • Pain & Pain Management (AREA)
  • Ophthalmology & Optometry (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pyridine Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Pyrane Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Heterocyclic Compounds Containing Sulfur Atoms (AREA)
  • Hydrogenated Pyridines (AREA)

Abstract

Patente de Invenção: "DERIVADOS DE áCIDO CARBâMICO E SUA APLICAçãO COMO LIGANTES DE RECEPTOR DE GLUTAMATO METABOTRóPICO". A presente invenção refere-se a compostos de fórmula (I) em que X siginifica O, S ou dois átomos de hidrogênio não formando uma ponte; A^ 1^/A^ 2^ siginificam, de modo independente um do outro, fenila ou um heterociclo de 6 elementos contendo 1 ou 2 átomos de nitrogênio; B é um grupo de fórmula (A) em que Y siginifica -O-, -S- ou uma ligação; Z siginifica -O- ou -S-; ou B é um grupo heterocíclico de 5 elementos de fórmulas (a, b, c ou d). Estes compostos podem ser usados como ligantes de receptores de glutamato metabotrópico no controle ou na prevenção de distúrbios neurológicos agudos e/ou crónicos.
BR0009885-0A 1999-04-20 2000-04-19 Derivados de ácido carbâmico e sua aplicação como ligantes de receptor de glutamato metabotrópico BR0009885A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP99107843 1999-04-20
PCT/EP2000/003556 WO2000063166A1 (en) 1999-04-20 2000-04-19 Carbamic acid derivatives and their use as metabotropic glutamate receptor ligands

Publications (1)

Publication Number Publication Date
BR0009885A true BR0009885A (pt) 2002-01-22

Family

ID=8238006

Family Applications (1)

Application Number Title Priority Date Filing Date
BR0009885-0A BR0009885A (pt) 1999-04-20 2000-04-19 Derivados de ácido carbâmico e sua aplicação como ligantes de receptor de glutamato metabotrópico

Country Status (32)

Country Link
US (2) US6462198B1 (pt)
EP (1) EP1171423B1 (pt)
JP (1) JP3751825B2 (pt)
KR (1) KR100497889B1 (pt)
CN (1) CN1228337C (pt)
AR (1) AR029626A1 (pt)
AT (1) ATE286875T1 (pt)
AU (1) AU776344B2 (pt)
BR (1) BR0009885A (pt)
CA (1) CA2367368C (pt)
CO (1) CO5160347A1 (pt)
CZ (1) CZ20013736A3 (pt)
DE (1) DE60017376T2 (pt)
ES (1) ES2234601T3 (pt)
HK (1) HK1045683B (pt)
HR (1) HRP20010761A2 (pt)
HU (1) HUP0201005A3 (pt)
IL (1) IL145665A (pt)
MA (1) MA26781A1 (pt)
MY (1) MY126586A (pt)
NO (1) NO20015064L (pt)
NZ (1) NZ514487A (pt)
PE (1) PE20010039A1 (pt)
PL (1) PL352825A1 (pt)
PT (1) PT1171423E (pt)
RU (1) RU2248349C2 (pt)
SI (1) SI1171423T1 (pt)
TR (1) TR200103010T2 (pt)
TW (1) TW593241B (pt)
WO (1) WO2000063166A1 (pt)
YU (1) YU73001A (pt)
ZA (1) ZA200107837B (pt)

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0005700D0 (en) * 2000-03-09 2000-05-03 Glaxo Group Ltd Therapy
IT1318636B1 (it) * 2000-07-21 2003-08-27 Roberto Pellicciari Derivati dell'acido 2- o 3- tenoico ad attivita' antagonista deirecettori del glutammato.
PL211061B1 (pl) * 2002-12-23 2012-04-30 Hoffmann La Roche Pochodne oksazolu, sposób ich wytwarzania, ich zastosowanie i kompozycja farmaceutyczna
BRPI0413347A (pt) 2003-08-06 2006-10-10 Senomyx Inc novos sabores, modificadores de sabor, agentes de sabor, realçadores de sabor, agentes de sabor e/ou realçadores umami ou doces, e utilização correspondente
MXPA06001480A (es) * 2003-08-06 2006-05-15 Pfizer Prod Inc Compuestos de oxazol para el tratamiento de trastornos neurodegenerativos.
KR20060088537A (ko) * 2003-09-06 2006-08-04 버텍스 파마슈티칼스 인코포레이티드 Atp-결합 카세트 수송체의 조절자
US20050222227A1 (en) * 2004-04-01 2005-10-06 Pfizer Inc Oxazole-amine compounds for the treatment of neurodegenerative disorders
EP1850681B1 (en) 2005-02-04 2019-12-18 Firmenich Incorporated Compounds comprising linked hetero aryl moieties and their use as novel umami flavor modifiers, tastants and taste enhancers for comestible compositions
TW200715993A (en) 2005-06-15 2007-05-01 Senomyx Inc Bis-aromatic amides and their uses as sweet flavor modifiers, tastants, and taste enhancers
EP3398452A3 (en) 2006-04-21 2018-11-28 Senomyx, Inc. Comestible compositions comprising high potency savory flavorants, and processes for producing them
JP2010510314A (ja) 2006-11-22 2010-04-02 シーサイド セラピューティクス,エルエルシー 精神遅滞、ダウン症候群、脆弱x症候群および自閉症の治療方法
US20080262066A1 (en) * 2007-04-20 2008-10-23 Green Cross Corporation Azole Derivatives as Cannabinoid CB1 Receptor Antagonists
EA018328B1 (ru) 2007-08-02 2013-07-30 Рекордати Айерленд Лимитед Новые гетероциклические соединения в качестве антагонистов метаботропных глутаматных рецепторов 5-го подтипа (мглу5)
EP2093234A1 (en) 2008-02-08 2009-08-26 Nutrinova Nutrition Specialties & Food Ingredients GmbH Oligopeptides for use as taste modulators
TWI429404B (zh) 2008-03-03 2014-03-11 Senomyx Inc 異山梨醇衍生物及彼等作為風味改良劑、促味劑及促味增強劑之用途
WO2010089119A1 (en) 2009-02-04 2010-08-12 Recordati Ireland Limited Heterocyclic derivatives as m-glu5 antagonists
WO2011029633A1 (en) 2009-09-14 2011-03-17 Recordati Ireland Limited Heterocyclic mglu5 antagonists
EP2544688B1 (en) 2010-03-02 2016-09-07 President and Fellows of Harvard College Methods and compositions for treatment of angelman syndrome
WO2011150380A1 (en) 2010-05-28 2011-12-01 Xenoport, Inc. Methods of treatment of fragile x syndrome, down's syndrome, autism and related disorders
MX2013000300A (es) 2010-07-09 2013-02-27 Recordati Ireland Ltd Nuevos compuestos espiroheterociclicos como antagonistas de mglu5.
WO2012009646A1 (en) 2010-07-15 2012-01-19 Xenoport, Inc. Methods of treating fragile x syndrome, down's syndrome, autism and related disorders
WO2012054724A1 (en) 2010-10-21 2012-04-26 Massachusetts Institute Of Technology Methods of treating seizure disorders
US8795673B2 (en) 2011-03-29 2014-08-05 Immunogen, Inc. Preparation of maytansinoid antibody conjugates by a one-step process
WO2012135517A2 (en) 2011-03-29 2012-10-04 Immunogen, Inc. Preparation of maytansinoid antibody conjugates by a one-step process
CN105209592A (zh) 2012-10-04 2015-12-30 伊缪诺金公司 使用pvdf膜纯化细胞结合剂细胞毒性剂缀合物
SG11201703599VA (en) 2014-11-19 2017-06-29 Immunogen Inc Process for preparing cell-binding agent-cytotoxic agent conjugates
WO2017121693A1 (de) 2016-01-15 2017-07-20 Bayer Pharma Aktiengesellschaft Substituierte thiazol- und thiadiazolamide und ihre verwendung
SG11201806478PA (en) 2016-02-05 2018-08-30 Immunogen Inc Efficient process for preparing cell-binding agent-cytotoxic agent conjugates
JP7471818B2 (ja) 2016-08-18 2024-04-22 ヴィダック ファーマ リミテッド ピペラジン誘導体、医薬組成物、及びその使用方法
WO2022050427A1 (ja) * 2020-09-07 2022-03-10 日産化学株式会社 1,3,4-オキサジアゾール-2-アミン化合物の製造方法

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5073566A (en) * 1989-11-30 1991-12-17 Eli Lilly And Company Angiotensin ii antagonist 1,3-imidazoles and use thereas
GB9626151D0 (en) 1996-12-17 1997-02-05 Lilly Industries Ltd Pharmaceutical compounds

Also Published As

Publication number Publication date
NO20015064D0 (no) 2001-10-18
ATE286875T1 (de) 2005-01-15
HUP0201005A2 (hu) 2002-07-29
TR200103010T2 (tr) 2002-05-21
CN1228337C (zh) 2005-11-23
KR100497889B1 (ko) 2005-06-29
CA2367368A1 (en) 2000-10-26
AU4749200A (en) 2000-11-02
HRP20010761A2 (en) 2002-12-31
AU776344B2 (en) 2004-09-02
IL145665A0 (en) 2002-06-30
MA26781A1 (fr) 2004-12-20
EP1171423B1 (en) 2005-01-12
CZ20013736A3 (cs) 2002-03-13
WO2000063166A1 (en) 2000-10-26
HK1045683A1 (en) 2002-12-06
ZA200107837B (en) 2002-12-23
SI1171423T1 (en) 2005-06-30
EP1171423A1 (en) 2002-01-16
CO5160347A1 (es) 2002-05-30
TW593241B (en) 2004-06-21
MY126586A (en) 2006-10-31
PL352825A1 (en) 2003-09-08
IL145665A (en) 2005-09-25
US20020091150A1 (en) 2002-07-11
NO20015064L (no) 2001-10-18
PT1171423E (pt) 2005-05-31
KR20010108518A (ko) 2001-12-07
CA2367368C (en) 2009-09-01
ES2234601T3 (es) 2005-07-01
CN1347406A (zh) 2002-05-01
US6462198B1 (en) 2002-10-08
NZ514487A (en) 2004-01-30
DE60017376T2 (de) 2006-03-02
YU73001A (sh) 2004-09-03
RU2248349C2 (ru) 2005-03-20
JP3751825B2 (ja) 2006-03-01
HUP0201005A3 (en) 2004-12-28
US6596743B2 (en) 2003-07-22
JP2002542229A (ja) 2002-12-10
PE20010039A1 (es) 2001-01-29
DE60017376D1 (de) 2005-02-17
HK1045683B (zh) 2006-02-03
AR029626A1 (es) 2003-07-10

Similar Documents

Publication Publication Date Title
BR0009885A (pt) Derivados de ácido carbâmico e sua aplicação como ligantes de receptor de glutamato metabotrópico
ATE438624T1 (de) 2-pyridonderivate mit affinität für den cannabinoid-typ-2-rezeptor
DE69801590T2 (de) Imidazolderivate und ihre verwendung als farnesylproteintransferase inhibitoren
HUP0301167A2 (hu) Neurológiai rendellenességek kezelésére felhasználható szulfonil-pirrolidin-származékok, eljárás az előállításukra, ezeket tartalmazó gyógyszerkészítmények és alkalmazásuk
BR9912621A (pt) Derivado de ácido aminometilcarboxìlico, composição farmacêutica, e, uso de um derivado de ácido aminometilcarboxìlico
BRPI0111596B8 (pt) Composto piridona, processo de produção do composto, composição farmacêutica, e uso do dito composto
HUP9903336A2 (hu) Szulfonsav-N-[(amino-imino-metil)-fenil]-aza-heretero-ciklil-amid származékok és az ezeket tartalmazó gyógyszerkészítmények
BR9812218A (pt) Novos derivativos de taxane
PT641328E (pt) Derivados aza-biciclicos em ponte como antagonistas da substancia p
BRPI0013667B8 (pt) derivados de glucopiranosiloxipirazol, composições medicinais contendo os mesmos e seus intermediários na produção deles
BRPI0409255A (pt) derivados de ácido 2-(8,9-dioxo-2,6-diazabi-ciclo(5.2.0)non-1(7)-en-2-il)alquil fosfÈnico e seu uso como antagonistas de receptores de d-asparto de -n-metila (nmda)
NO974890D0 (no) Radicicolderivater
MX2010003983A (es) 5,6-diarilpiridinas sustituidas en la posicion 2 y 3, su preparacion y su uso terapeutico.
FR2800735B1 (fr) Nouvelles aralkyle-1,2-diamines possedant une activite calcimimetique et leur mode de preparation
NO995590D0 (no) 20-Aryl-5<alfa>-pregnan-derivater
BR9815920A (pt) Compostos aza-heterocìclicos usados para tratar distúrbios neurológicos e queda de cabelo
ATE113035T1 (de) 1,4-dihydropyridin-derivate und diese enthaltende pharmazeutische zusammensetzungen.
GB1530768A (en) 2-substituted-4-amino-6,7-dimethoxyquinazolines
ATE159029T1 (de) Phosphonsäurederivate, verfahren zur herstellung und ihre verwendung
BR0214488A (pt) Derivados de benzotiazol
EP1123923A4 (en) DIHYDROPYRIDINE DERIVATIVES AND DRUG BLOCK CONTAINING THESE
BR9902653A (pt) Derivados de di-ou triaza-espiro [4,5] decano
UA41340C2 (uk) Похідні циклогексанкарбонової кислоти, суміш їх ізомерів або окремі ізомери і фізіологічно прийнятні солі і фармацевтична композиція з активністю, що гальмує ферментний комплекс глюкоза-6-фосфатази
DK1373218T3 (da) Imidazolylderivater til anvendelse som histamin H3-receptorligander
BR9800956A (pt) Composição farmacêutica que age por inibição das serinas proteases, e, medicamento

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 9A ANUIDADE.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: REFERENTE AO DESPACHO 8.6 NA RPI2003 DE 26/05/2009.